Europe Autoimmune Disease Diagnostics Market size crossed USD 320 million in 2021 and is poised to witness 6% CAGR from 2022 to 2028. As the incidence of rare autoimmune diseases rises, the need for effective diagnostic technologies is taking priority.
Get more details on this report - Request Free Sample PDF
Over the last few years, the prevalence rate of autoimmune conditions such as type 1 diabetes mellitus, systemic lupus erythematosus, rheumatoid arthritis, Graves’ disease, and multiple sclerosis, has been steadily increasing. Since primary immune deficiencies are extremely varied in terms of symptoms and degrees of severity, patients can have problems in availing proper therapeutic and diagnostic solutions. Several companies are addressing this pain point by launching AI-powered technologies for delivering more accurate and faster results.
It is estimated that more than 5% to 10% of the population in Europe is affected with autoimmune diseases. It has realized the considerable need for spreading awareness about the disorders and make sure people have enough access to suitable diagnosis and treatments. The severity can be understood from the fact that over 4 million people across the UK suffer from at least one autoimmune disorder. The gradual rise in patients throughout Europe will bolster the efforts to promote early diagnosis of conditions and increase the footfall across diagnostic centers.
Impact of COVID-19 on Europe Autoimmune Disease Diagnostics Market Outlook
The novel coronavirus pandemic has encouraged reliance on self-tests among people, for taking charge of medical needs. Companies are likely to focus on diverse segments such as diabetes patients and those with high cholesterol. Over the last couple of years, home-based blood tests for autoimmune diseases have been gaining traction due to the social restrictions imposed by governments worldwide.
Decreased mobility of patients suffering from chronic conditions has been a key factor supporting the uptake of these products. In June 2021, Lithuania-based start-up Revolab, announced that it has developed a digital platform for tracking the overall physical wellbeing of users through a home blood test kit as well as a smartphone app, indicating future development scope across the diagnostics domain.
Europe Autoimmune Disease Diagnostics Market, By Test Type
The autoantibody tests segment accounted for USD 100 million revenue in 2021, due to increasing cases of systemic autoimmune conditions such as lupus and rheumatoid arthritis. As these tests are conducted using a host of devices and techniques, the installation of X-ray equipment, MRI devices, and other imaging scans, is expected to see an uptick. Several medical professionals have displayed preference for antinuclear antibody (ANA) tests for autoimmune disorders to ensure more accurate and timely diagnosis.
Europe Market, By Product
The localized autoimmune disease diagnostics market in Europe is anticipated to register notable gains through 2028. Today, standardized immunoassay kits are available to facilitate early detection of various diseases. Autoimmune diseases specific to certain organs can be diagnosed using suitable solutions. Government efforts for improving patient awareness regarding the diseases such as celiac disease and Crohn’s disease will strengthen the industry outlook.
Europe Market, By Country
France autoimmune disease diagnostics market size is expected to rise substantially during the forecast timeline. In January 2021, the French government introduced the ATRACTion program, which has received funds worth nearly USD 9.83 million. Under this program, over 11 key regional healthcare players will collaborate to develop precision medicine for patients suffering from immune deficiencies, as well as transform areas such as diagnosis and prognosis. France also has a strong healthcare sector with advanced infrastructure in place. The country had spent more than USD 209 billion on healthcare in 2020.
Competitive Industry Landscape
Prominent participants operating across the Europe autoimmune disease diagnostics market are Beckman Coulter, Inc., SQI diagnostics, Hemagen Diagnostics, Abbott Laboratories, Siemens Healthineers, Quest Diagnostics, Crescendo Bioscience, Inc., F. Hoffmann-La Roche Ltd, and SQI diagnostics.
These companies have been foraying into new patient segments with innovative devices for gaining a higher industry share. For instance, in August 2022, industry leader Thermo Fisher Scientific Inc (TMO) announced that it has successfully secured FDA clearance for its new in vitro diagnostic tools for detecting sesame and wheat allergies. The advanced blood tests will serve as a major diagnostic aid for clinicians and doctors to identify severity of allergic reactions caused by foods such as milk, eggs, and peanuts. Since wheat allergy can be often linked with celiac disease, an autoimmune condition, this development represents a positive bearing for the industry.